Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Expanded Access Program (EAP) for SPG302 in the United States (U.S.) for people living with Amyotrophic Lateral Sclerosis (ALS)

Next Previous
Trial Profile

An Expanded Access Program (EAP) for SPG302 in the United States (U.S.) for people living with Amyotrophic Lateral Sclerosis (ALS)

Status: Planning
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 09 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SPG 302 (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Expanded access; Therapeutic Use
  • Sponsors Spinogenix

Most Recent Events

  • 09 May 2025 New trial record
  • 05 May 2025 Accoriding to Spinogenix media release, the company has received notification from the Food and Drug Administration (FDA) to begin its Expanded Access Program (EAP)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top